Haghighi, Melika, Khorasani, Akbar, Karimi, Pegah, Mahdavi, Mehdi. (1401). Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses. , 25(5), 554-561. doi: 10.22038/ijbms.2022.63527.14015
Melika Haghighi; Akbar Khorasani; Pegah Karimi; Mehdi Mahdavi. "Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses". , 25, 5, 1401, 554-561. doi: 10.22038/ijbms.2022.63527.14015
Haghighi, Melika, Khorasani, Akbar, Karimi, Pegah, Mahdavi, Mehdi. (1401). 'Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses', , 25(5), pp. 554-561. doi: 10.22038/ijbms.2022.63527.14015
Haghighi, Melika, Khorasani, Akbar, Karimi, Pegah, Mahdavi, Mehdi. Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses. , 1401; 25(5): 554-561. doi: 10.22038/ijbms.2022.63527.14015

Improvement of the inactivated SARS-CoV-2 vaccine potency through formulation in alum/naloxone adjuvant; Robust T cell and anti-RBD IgG responses

Iranian Journal of Basic Medical Sciences
مقاله 2، دوره 25، شماره 5، مرداد 2022، صفحه 554-561    اصل مقاله (738.21 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/ijbms.2022.63527.14015
نویسندگان
Melika Haghighi1، 2؛ Akbar Khorasani3؛ Pegah Karimi1، 2؛ Mehdi Mahdavi* 1، 2، 4
1Advanced Therapy Medicinal Product (ATMP) Department, Breast Cancer Research Center, Motamed Cancer Institute, Academic Center for Education, Culture and Research (ACECR), Tehran, Iran
2Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran
3Department of FMD Vaccine Production, Razi Vaccine & Serum Research Institute, Agricultural Research, Education & Extension Organization (AREEO), Karaj, Iran
4Immunotherapy Group, The Institute of Pharmaceutical Science (TIPS), Tehran University of Medical Science, Tehran, Iran
چکیده
Objective(s): SARS-CoV-2, emerging as a major threat to public health, has to be controlled through vaccination. Naloxone (NLX), an opioid receptor antagonist, demonstrated its adjuvant activity for microbial vaccines. In this study, inactivated SARS-CoV-2 was developed in the Alum/NLX adjuvant to increase the potency of the inactivated SARS-CoV-2 vaccine. 
Materials and Methods: BALB/c mice were immunized on days 0 and 14 with inactivated SARS-CoV-2-Alum, -Alum + NLX 3 mg/kg, -Alum + NLX 10 mg/kg, and -Freund adjuvant, as well as PBS. IFN-γ and IL-4 cytokines and Granzyme-B release were assessed with ELISA. In addition, specific total IgG, IgG1/IgG2a isotypes, and ratio as well as anti-RBD IgG responses were assessed with an optimized ELISA. 
Results: SARS-CoV-2-Alum-NLX10 group showed a significant increase in the IFN-γ cytokine response versus SARS-CoV-2-Alum, SARS-CoV-2-Alum-NLX3, and PBS groups. The SARS-CoV-2-Alum-NLX3 group exhibited a significant decrease in IL-4 cytokine versus SARS-CoV-2-Alum. The mice immunized with SARS-CoV-2-Alum-NLX10 showed a significant increase in CTL activity versus SARS-CoV-2-Alum and PBS. In addition, mice immunized with SARS-CoV-2-Alum-NLX3, SARS-CoV-2-Alum-NLX10 and SARS-CoV-2-Freund demonstrated an increase in IgG response, as compared with SARS-CoV-2-Alum and PBS group. Furthermore, all formulations of SARS-CoV-2 vaccines could induce both IgG1 and IgG2a isotypes. But, the IgG2a/IgG1 ratio in SARS-CoV-2-Freund and SARS-CoV-2-Alum-NLX10 revealed an increase as compared with that of the SARS-CoV-2-Alum group. Anti-RBD IgG response in the SARS-CoV-2-Alum-NLX10 group showed a significant increase as compared with the Alum-based vaccine. 
Conclusion: Formulation of inactivated SARS-CoV-2 virus in NLX/alum adjuvant improved the potency of humoral and, especially, cellular responses.
کلیدواژه‌ها
Alum Adjuvant؛ Immune responses؛ Inactivated SARS-CoV-2 - virus؛ Naloxone؛ Vaccine formulation
مراجع
آمار
تعداد مشاهده مقاله: 1,047
تعداد دریافت فایل اصل مقاله: 679
دانشگاه علوم پزشکی مشهد
آمار
تعداد نشریات29
تعداد شماره‌ها2,325
تعداد مقالات24,885
تعداد مشاهده مقاله83,026,915
تعداد دریافت فایل اصل مقاله46,028,567
اخبار نشریات